These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21190594)

  • 1. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    J Exp Clin Cancer Res; 2010 Dec; 29(1):172. PubMed ID: 21190594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor.
    Schultz J; Lorenz P; Ibrahim SM; Kundt G; Gross G; Kunz M
    Mol Carcinog; 2009 Jan; 48(1):14-23. PubMed ID: 18459127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma.
    Zhu Y; Gao XM; Yang J; Xu D; Zhang Y; Lu M; Zhang Z; Sheng YY; Li JH; Yu XX; Zheng Y; Dong QZ; Qin LX
    Cancer Sci; 2018 Mar; 109(3):710-723. PubMed ID: 29285854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA.
    Chen RX; Xia YH; Xue TC; Zhang H; Ye SL
    Oncol Rep; 2011 Mar; 25(3):803-8. PubMed ID: 21174062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma.
    Zhao J; Lu B; Xu H; Tong X; Wu G; Zhang X; Liang A; Cong W; Dai J; Wang H; Wu M; Guo Y
    Hepatology; 2008 Jul; 48(1):265-75. PubMed ID: 18537194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interference of osteopontin expression inhibits the invasion and metastasis of human hepatocellular carcinoma cell lines].
    Lin F; Li YY; Xia JT; Wen MJ; Lai YY; Cai WS; Wu ZF; Fan SF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jun; 17(6):422-5. PubMed ID: 19567019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Segment-specific targeting via RNA interference mediates down-regulation of OPN expression in hepatocellular carcinoma cells.
    Lin F; Huang CM; Cao J; Pei ZH; Gu WL; Fan SF; Li KP; Lin CM
    Genet Mol Res; 2015 Nov; 14(4):14440-7. PubMed ID: 26600502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection.
    Deng B; Zhang XF; Zhu XC; Huang H; Jia HL; Ye QH; Dong QZ; Qin LX
    Oncol Rep; 2013 Dec; 30(6):2795-803. PubMed ID: 24065086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer.
    Emani S; Zhang J; Guo L; Guo H; Kuo PC
    Surgery; 2008 Jun; 143(6):803-12. PubMed ID: 18549897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines.
    Bhattacharya SD; Garrison J; Guo H; Mi Z; Markovic J; Kim VM; Kuo PC
    Surgery; 2010 Aug; 148(2):291-7. PubMed ID: 20576283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression.
    Chen RX; Xia YH; Xue TC; Ye SL
    Mol Biol Rep; 2011 Aug; 38(6):3671-7. PubMed ID: 21104439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells.
    Lin F; Li Y; Cao J; Fan S; Wen J; Zhu G; Du H; Liang Y
    Mol Biol Rep; 2011 Nov; 38(8):5205-10. PubMed ID: 21188534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes.
    Iqbal J; McRae S; Banaudha K; Mai T; Waris G
    J Biol Chem; 2013 Dec; 288(52):36994-7009. PubMed ID: 24240095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of microRNA-96 expression inhibits the invasion of hepatocellular carcinoma cells.
    Chen RX; Xia YH; Xue TC; Ye SL
    Mol Med Rep; 2012 Mar; 5(3):800-4. PubMed ID: 22160187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells.
    Zhang J; Guo H; Mi Z; Gao C; Bhattacharya S; Li J; Kuo PC
    Exp Cell Res; 2009 Jan; 315(2):304-12. PubMed ID: 19026636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC.
    Ding K; Fan L; Chen S; Wang Y; Yu H; Sun Y; Yu J; Wang L; Liu X; Liu Y
    Oncol Rep; 2015 Dec; 34(6):3297-303. PubMed ID: 26397192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma.
    Takafuji V; Forgues M; Unsworth E; Goldsmith P; Wang XW
    Oncogene; 2007 Sep; 26(44):6361-71. PubMed ID: 17452979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma.
    Zapf MA; Kothari AN; Weber CE; Arffa ML; Wai PY; Driver J; Gupta GN; Kuo PC; Mi Z
    Surgery; 2015 Oct; 158(4):1039-47; discussion 1047-8. PubMed ID: 26189955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway.
    Cao L; Fan X; Jing W; Liang Y; Chen R; Liu Y; Zhu M; Jia R; Wang H; Zhang X; Zhang Y; Zhou X; Zhao J; Guo Y
    Oncotarget; 2015 Mar; 6(9):6627-40. PubMed ID: 25749383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner.
    Phillips RJ; Helbig KJ; Van der Hoek KH; Seth D; Beard MR
    World J Gastroenterol; 2012 Jul; 18(26):3389-99. PubMed ID: 22807608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.